June 03, 2020

IBRI RESEARCH PUBLISHED: Pre-clinical Evaluation of TYK2 Inhibitors for Human Beta Cell Protection in Type 1 Diabetes

Abstract: Aims: Type 1 diabetes (T1D) is a chronic autoimmune disease leading to progressive loss of pancreatic beta cells. Interferon (IFN)-α plays a critical role in the crosstalk between...

May 29, 2020

IBRI IN THE NEWS: Pushing Hard for a COVID-19 Vaccine

The race is on. Around the world, more than 80 vaccine projects are under development by pharmaceutical companies and university research laboratories scrambling to find a way to slow...

May 26, 2020

New Research Identifies Two Classes of Drugs that Could be Re-purposed for the Early Treatment of T1D

INDIANAPOLIS - Researchers from the Indiana Biosciences Research Institute (IBRI), a leading independent, industry-inspired applied research institute, and Université Libre de Bruxelles (ULB) Center for Diabetes Research, identified two classes...

May 13, 2020

IBRI RESEARCH PUBLISHED: Pancreatic ß-cells in Type 1 and Type 2 Diabetes Mellitus: Different Pathways to Failure

Abstract: Loss of functional β-cell mass is the key mechanism leading to the two main forms of diabetes mellitus — type 1 diabetes mellitus (T1DM) and type 2 diabetes...

April 21, 2020

IBRI RESEARCH PUBLISHED: SUMOylation, a multifaceted regulatory mechanism in the pancreatic beta cells

Abstract SUMOylation is an evolutionarily conserved post-translational modification (PTM) that regulates protein subcellular localization, stability, conformation, transcription and enzymatic activity. Recent studies indicate that SUMOylation plays a key role...

April 16, 2020

IBRI IN THE NEWS: IBRI Names Scientific Director

INDIANAPOLIS - The Indiana Biosciences Research Institute has named Investigator Decio Eizirik as Scientific Director of the IBRI Diabetes Center. Eizirik will focus on recruiting early career investigators and defining...

April 15, 2020

IBRI Names Decio Eizirik Scientific Director of its IBRI Diabetes Center

INDIANAPOLIS, IND. – The Indiana Biosciences Research Institute (IBRI) is pleased to announce that it has named Investigator Decio Eizirik, MD, PhD, Scientific Director of its IBRI Diabetes Center (IDC)....

April 13, 2020

IBRI RESEARCH PUBLISHED: The T1D-associated lncRNA Lnc13 modulates human pancreatic ß cell inflammation by allele-specific stabilization of STAT1 mRNA

The mechanisms by which autoimmunity is amplified in type 1 diabetes (T1D) remain to be clarified, and the lack of this understanding hampers efforts to prevent or arrest the disease....

March 30, 2020

IBRI RESEARCH PUBLISHED: Hypusinated eIF5A is expressed in the pancreas and spleen of individuals with type 1 and type 2 diabetes

ABSTRACT The gene encoding eukaryotic initiation factor 5A ( EIF5A ) is found in diabetes-susceptibility loci in mouse and human. eIF5A is the only protein known to contain hypusine...

March 31, 2020

IBRI RESEARCH PUBLISHED: Utilization of Electronic Health Records for the Assessment of Adiponectin Receptor Autoantibodies during the Progression of Cardio-metabolic Comorbidities

ABSTRACT Background : Diabetes is a complex, multi-symptomatic disease that drives healthcare costs through its complications as the prevalence of this disease grows rapidly world-wide. Real-world electronic health records...

First 1 2 3 4 5  ... Last 
2020 Annual Report cover

The IBRI 2020 Annual Report is now available. The report theme, ‘Shaping the Future of Translational Science,’ reflects the IBRI’s commitment to turning scientific discovery into improved outcomes for patients.